Amendment extends lease through 2016 with options through 2026 PRINCETON, N.J., April 25 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, announced today that they have entered into a lease amendment with 201 College Road Associates, LLC for its 57,000 square foot manufacturing and headquarters facility. Under the agreement, Laureate Pharma will extend its current lease through 2016 and will have two additional five-year options to extend the lease through 2026. Financial terms of the agreement were not disclosed. (Logo: http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO ) "This agreement is an important strategic milestone for Laureate Pharma, said Robert J. Broeze, Ph.D., President and CEO of Laureate Pharma. "We have made significant capital investments in the facility during the last five years and our facility master plan provides additional opportunities for expansion in the future. Securing the Princeton facility lease for the long term demonstrates Laureate's commitment to our customers, employees and investors." Laureate's Princeton facility provides a full range of bioprocessing services including process development, cGMP scale production up to 2000L scale, formulation and filling. In 2006, Laureate began the facility expansion project to add a pilot plant and other equipment to expand the capacity of the facility. "Laureate Pharma is a valued tenant that has made many impressive capital improvements to the Princeton facility." said Peter Dodds, Principal of Morford & Dodds Realty, Inc., Ownership representatives. "We are pleased that they continue to grow their business and are able to extend their lease at this time." About Laureate Pharma, Inc. Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a partner company of Safeguard Scientifics, Inc. (NYSE: SFE; http://www.safeguard.com/). For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at (609) 919-3400, or or visit http://www.laureatepharma.com/. http://www.newscom.com/cgi-bin/prnh/20020723/LPHARMLOGO DATASOURCE: Laureate Pharma, Inc. CONTACT: Michael Cavanaugh, Vice President Sales, Marketing, and Business Development for Laureate Pharma, Inc., +1-609-919-3400, or Web site: http://www.laureatepharma.com/ http://www.safeguard.com/

Copyright